zilovertamab,ibrutinib
janssen,oncternal therapeutics,abbvie
['zilovertamab', 'cll', '1924', '3313', ' ibru', 'fil,veral,12', '1659', 'lymsm', 'emergent ']
phase i/ii of zilovertamab (ror1 mab) + ibrutinib in r/r mcl/mzl/cll. ~50% tp53mut. 10% gr 3 htn, 9% afib (doesn't sound 'well tolerated' to me). orr was same as ibr alone in cll? worse survival in high-risk mcl. maybe an option in mcl with different btk. #ash22 #lymsm 
#lymsm & #mmsm hematologist & patient-reported outcomes researcher @CUHematology. Founder of https://t.co/kN6qeGXfg5, @inTrainingDoc & @inHouseMag. ??????